Retatrutide remains investigational as of 2026. It is not FDA-authorized and can't be prescribed or compounded outside of medical demo participation. Switching to an unapproved investigational peptide isn't a possibility outside of trial participation. TrimrX continues to observe retatrutide's improvement closely, and we will integrate it into p